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ARTICLE
Broadly neutralizing monoclonal antibodies protect
against multiple tick-borne flaviviruses
Laura A. VanBlargan1*, John M. Errico2*, Natasha M. Kafai1,2, Katherine E. Burgomaster3, Prashant N. Jethva4, Rebecca M. Broeckel5,
Kimberly Meade-White5, Christopher A. Nelson2, Sunny Himansu6, David Wang7, Scott A. Handley2, Michael L. Gross4, Sonja M. Best5,
Theodore C. Pierson3, Daved H. Fremont2,7,8,9, and Michael S. Diamond1,2,7,9
Although Powassan virus (POWV) is an emerging tick-transmitted flavivirus that causes severe or fatal neuroinvasive disease
in humans, medical countermeasures have not yet been developed. Here, we developed a panel of neutralizing anti-POWV
mAbs recognizing six distinct antigenic sites. The most potent of these mAbs bind sites within domain II or III of the envelope
(E) protein and inhibit postattachment viral entry steps. A subset of these mAbs cross-react with other flaviviruses. Both
POWV type–specific and cross-reactive neutralizing mAbs confer protection in mice against POWV infection when given as
prophylaxis or postexposure therapy. Several cross-reactive mAbs mapping to either domain II or III also protect in vivo
against heterologous tick-transmitted flaviviruses including Langat and tick-borne encephalitis virus. Our experiments define
structural and functional correlates of antibody protection against POWV infection and identify epitopes targeted by broadly
neutralizing antibodies with therapeutic potential against multiple tick-borne flaviviruses.
Introduction
Powassan virus (POWV) is an emerging tick-borne flavivirus
(TBFV) that circulates in parts of North America and Russia.
Although human disease associated with POWV is relatively
rare, the last two decades have been characterized by a >600%
rise in cases compared with the four prior decades (Fatmi et al.,
2017). POWV can cause severe neurological disease in humans
after a tick bite or blood transfusion from an infected donor
(Taylor et al., 2021). Neuroinvasive POWV infection has a high
case fatality rate (10–15%), with over 50% of survivors experi-
encing substantive long-term neurological sequelae (Ebel, 2010;
Hermance and Thangamani, 2017).
The two serologically and clinically indistinguishable distinct
lineages of POWV circulating in North America, lineages I and II
(also called deer-tick virus [DTV]), share at least 96% amino
acid–sequence identity in their envelope (E) glycoproteins. De-
spite this genetic similarity, the two lineages are transmitted by
different tick vectors; POWV lineage I strains are maintained
predominantly in Ixodes cookei ticks, whereas lineage II strains
are carried primarily by Ixodes scapularis (deer ticks; Ebel et al.,
2001). Since deer ticks are more aggressive at biting humans,
lineage II viruses cause the majority of infections in North
America (Hermance and Thangamani, 2017).
TBFVs are classified phylogenetically into three groups: the
mammalian, seabird, and Kadam virus groups (Grard et al.,
2007). The mammalian TBFVs include viruses that cause en-
cephalitis (including tick-borne encephalitis virus [TBEV] and
POWV) or hemorrhagic fever in humans, as well as viruses not
linked to human disease, such as Gadgets Gully virus (GGYV).
The E proteins of the mammalian TBFV group share ≥70% amino
acid identity, whereas they share only ∼38–45% identity with E
proteins of mosquito-borne flaviviruses (MBFVs).
There are no licensed vaccines or therapies for POWV in-
fection. Although there are effective inactivated virus vaccines
against TBEV, there are still ∼10,000 cases annually due to
variable vaccination rates (Kubinski et al., 2020). Anti-TBEV
serum Ig has been used as postexposure treatment for TBEV,
although its current use is limited by safety concerns (Bröker
and Kollaritsch, 2008; Charrel et al., 2004). Antibodies elicited
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by TBEV vaccination, while capable of cross-neutralizing more
closely related TBFVs including Omsk hemorrhagic fever, Ky-
asanur forest disease, and Alkhurma hemorrhagic fever viruses,
showed limited capacity to neutralize the more distantly related
POWV (McAuley et al., 2017).
Previously, we demonstrated that an mRNA vaccine encod-
ing the prM and E proteins of POWV lineage II strain Spooner
(POWV-SPO) induced neutralizing antibodies in mice that in-
hibited infection in vitro of several strains of POWV and other
TBFVs (VanBlargan et al., 2018). The humoral immune response
elicited by the vaccine was sufficient to mediate protection, as
passive transfer of immune serum to naive mice prevented le-
thality and viremia following POWV challenge. Here, we further
evaluated the protective components of the humoral immune
response to POWV infection by developing a panel of neutral-
izing mAbs isolated from mice immunized with the POWV
mRNA vaccine or infected with POWV-SPO. Themost protective
antibodies in vivo block postattachment steps in the viral life
cycle and recognize epitopes on the lateral ridge/C-C9 loop or
A-strand of domain III (DIII) or the fusion loop of domain II (DII)
in the E protein. Several of these antibodies cross-react with
other TBFVs and protect against heterologous virus challenge.
Finally, structural analysis of POWV DIII bound by POWV-80
reveals the molecular determinants of cross-reactivity and
cross-protection.
Results
Development of anti-POWV mAbs
To gain insight into the protective humoral immune response
against POWV, we generated a panel of mAbs from C57BL/6J
mice that were infected with POWV strain SPO or had received a
POWV mRNA vaccine (VanBlargan et al., 2018). 84 hybridomas
producing anti-POWV antibodies were isolated using flow cy-
tometry and ELISA-based screens with infected cells and re-
combinant POWV E protein. These mAbs were cloned by
limiting dilution, and 21 mAbs were selected for further study
(Table 1) based on neutralization of POWV by hybridoma
supernatants.
The 21 selected mAbs were purified and isotyped. Most mAbs
were IgG2c, although three (POWV-18, POWV-48, and POWV-
71) were of the IgG2b subclass (Table 1). These 21 mAbs were
characterized for competitive binding to E protein by ELISA. The
mAbs separated into six competition groups (A–F) based on their
ability to block binding of other mAbs to E protein (Fig. 1 A and
Table 1). POWV-16 did not bind E protein by ELISA, and thus it
was not placed in a competition group. Western blotting of
POWV-infected cell lysates with POWV-16 revealed two bands at
∼55 and 18 kD, suggesting it likely engages an epitope spanning
the prM and E proteins (Fig. S1 A). This panel of mAbs also was
tested for their ability to bind recombinant DIII of the E protein;
all mAbs in groups E and F bound DIII, indicating that two dis-
tinct epitopes on DIII were targeted.
The variable region of eachmAb genewas sequenced. Several
mAbs shared VH gene usage and had high sequence similarity
(90% or greater; Fig. S1, B and C; and Table 1). Generally, mAbs
that shared high sequence similarity were in the same
competition groups. The exception was POWV-4 in group A and
POWV-14 in group B, which shared VH gene usage but fell into
separate competition groups. Notably, these two mAbs shared
lower sequence homology than other related antibodies (∼88%)
and had more divergent CDR3 sequences (Fig. S1, B and C),
which likely explains their distinct binding specificities.
Neutralizing activity of anti-POWV mAbs
We tested the panel of 21 mAbs for neutralization potency using
a reporter virus particle (RVP)–based neutralization assay. RVPs
were produced with the C-prM-E proteins of the POWV lineage
II strain P0375 and were used for infection of Raji-DCSIGN-R
cells (VanBlargan et al., 2018). All 21 mAbs neutralized POWV
RVP infection, with half-maximal effective concentration
(EC50) values ranging from 6 to 803 ng/ml (Table 1). Group B
mAbs POWV-54, -56, and -63 were the most potently inhibitory
(EC50 < 10 ng/ml), followed by POWV-16 (10 ng/ml) and group F
mAbs POWV-55, -60, and -61 (16–19 ng/ml).
We next evaluated neutralization potency using focus-
reduction neutralization tests (FRNTs) against three authentic
viral isolates: POWV lineage I strain LB (1958; Ontario, Canada),
lineage II strain SPO (1997; Spooner, WI), and lineage II strain
MA51240 (2008; Spooner, WI). As seen with other flaviviruses
(Dowd et al., 2016a), the neutralization potency of mAbswas less
when determined by FRNT than by RVP-based assay (Table 1).
Nonetheless, all mAbs inhibited infection of all three POWV
strains by FRNT with the exception of POWV-16 (which did not
neutralize any strain) and POWV-15 and -23 (which did not
neutralize POWV-LB; Fig. 1, B and C; and Table 1). Overall, the
mAbs showed weaker neutralization potency against POWV-
SPO and POWV-LB by FRNT (EC50 > 1 µg/ml) than against
POWV-MA51240, even though they were raised against viral
proteins from POWV-SPO.
To understand the basis for the differential potency of mAb
neutralization of POWV-MA51240 and POWV-SPO, we se-
quenced both viruses and identified three coding differences in
the viral polyprotein: K213N, T2369S, and R2903K. Only one of
the changes, K213N, is in a structural protein, whereas the other
substitutions are in NS4B and NS5, respectively. Polyprotein
residue K213 corresponds to prM residue K101 and is retained on
the virion as M residue K10 following pr cleavage and dissoci-
ation during viral maturation (Fig. S1 D). To test whether the
K10N substitution inMmodulates neutralizing activity of anti-E
mAbs against POWV-MA51240, we introduced the change into
an infectious clone of POWV-SPO (Kenney et al., 2018) and as-
sessed activity of several DIII mAbs. Remarkably, all five mAbs
tested (POWV-33, -55, -60, -61, and -80) showed greater neu-
tralizing activity against the M-K10N mutant than WT POWV-
SPO (80- to 100-fold; Fig. 1, D and E). Thus, variation at residue
10 of the M protein affects the neutralizing potency of anti–E
protein mAbs against POWV.
Although a structure of POWV M is not available, the E-M
dimer structure of the related TBEV shows that the M protein
consists of an N-terminal loop, one perimembrane helix, and
two transmembrane helices (Fig. S1 E; Füzik et al., 2018). The M
protein is not exposed on the surface of the virion. Most of theM
protein is adjacent to or embedded within the viral membrane,
VanBlargan et al. Journal of Experimental Medicine 2 of 22
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with the N-terminal loop located between the viral membrane
and the E protein. This N-terminal loop, where M residue 10 is
located, interacts with DII of the E protein (Füzik et al., 2018).
Due to the proximity of K10N to the site of prM cleavage, we
hypothesized that the substitution might impact POWV matu-
ration, which globally can modulate neutralization sensitivity of
anti–E protein mAbs (Nelson et al., 2008). We assessed the
impact of virion maturation on the neutralization sensitivity of
the two POWV strains by producing viruses in Vero cells over-
expressing furin (Mukherjee et al., 2016); viruses propagated in
these cells have greater prM cleavage and more mature virus
populations than stocks produced in conventional Vero cells.
The maturation state of the viral stocks was assessed by ELISA
using the anti–prM-E antibody POWV-16. Both WT andM-K10N
POWV-SPO produced in Vero-furin cells had lower prM
content than either standard preparation (Fig. 1 F). A standard
preparation of POWV-SPO M-K10N retained more uncleaved
prM than WT POWV-SPO; similarly, Vero-furin cell–derived
M-K10N virus had more uncleaved prM than Vero-furin cell–
derived WT POWV-SPO (Fig. 1 F). These data indicate that the
M-K10N substitution results in higher levels of uncleaved prM
in virions, even in the presence of furin overexpression. To
probe the functional effect of pr cleavage on neutralization
sensitivity, we assessed neutralization of standard and Vero-
furin cell preparations of WT and M-K10N POWV-SPO with 10
mAbs (POWV-4, -5, -14, -15, -23, -37, -56, -60, -65, and -70) with
Table 1. POWV mAb competition group and neutralization potency
Competition
group












None POWV-16 IGHV1-39*01 IgG2c None N/A N/A 10 >20,000 >20,000 >20,000
A POWV-4 IGHV1-62-
2*01
IgG2c E 9.7 ± 1.7 285 43 3,658 368 10,856
B POWV-5 IGHV1-50*01 IgG2c E 2.8 ± 0.47 2,214 311 6,631 1,049 5,269
POWV-18 IGHV1-50*01 IgG2b E 3.2 ± 0.81 2,390 803 8,507 1,578 10,504
POWV-
54
IGHV1-26*01 IgG2c E 1.3 ± 0.2 3,536 9 1,757 231 2,260
POWV-63 IGHV1-26*01 IgG2c E 3.2 ± 0.4 721 6 5,018 223 2,999
POWV-56 IGHV1-53*01 IgG2c E 2.0 ± 0.41 1,724 6 2,612 310 726
C POWV-14 IGHV1-62-
2*01
IgG2c E 1.7 ± 0.98 2,740 122 4,085 340 12,248
POWV-15 IGHV1-15*01 IgG2c E 23 ± 1.91 171 358 10,840 660 >20,000
POWV-23 IGHV1-67*01 IgG2c E 4.0 ± 0.68 1,920 111 3,800 318 >20,000
D POWV-
48
IGHV1-34*01 IgG2b E 3.6 ± 0.12 1,075 234 5,395 434 3,149
POWV-62 IGHV1-34*01 IgG2c E 0.6 ± 0.43 1,998 83 2,412 226 843
POWV-
70
IGHV1-34*01 IgG2c E 1.6 ± 0.39 1,853 87 1,358 202 1,054
E POWV-33 IGHV1-75*01 IgG2c E, DIII 2.5 ± 0.05 1,066 95 5,307 162 7,577
POWV-37 IGHV1-75*01 IgG2c E, DIII 1.8 ± 0.17 837 51 3,455 127 8,411
POWV-65 IGHV1-22*01 IgG2c E, DIII 1.5 ± 0.17 2,840 102 7,955 110 4,854
POWV-71 IGHV1-54*01 IgG2b E, DIII 0.6 ± 0.26 4,151 27 14,924 339 6,789
POWV-
80
IGHV5-16*02 IgG2c E, DIII 34.7 ± 4.47 84 104 12,060 83 17,962
F POWV-55 IGHV14-3*01 IgG2c E, DIII 1.2 ± 0.35 1,066 16 1,764 23 5,410
POWV-
60
IGHV14-3*01 IgG2c E, DIII 1.9 ± 0.58 857 19 2,621 21 6,913
POWV-61 IGHV14-3*01 IgG2c E, DIII 2.1 ± 0.19 1,122 16 1,839 21 4,463
N/A, not available.
amAbs were assessed for binding to recombinant POWV E protein and DIII of the E protein by ELISA.
bExample kinetic binding curves with fits shown in Fig. S4.
cNeutralization of POWV strains was assessed by FRNT or an RVP-based assay where noted. EC50 values were determined by nonlinear regression. Geometric
mean from three or four independent experiments.
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Figure 1. Anti-POWV neutralizing mAbs cluster into six competition groups. (A) Competition ELISA for mAb binding to POWV E protein. Binding of each
biotinylated antibody in the presence of each blocking antibody is expressed relative to binding to POWV E in the absence of a blocking antibody. Mean of three
VanBlargan et al. Journal of Experimental Medicine 4 of 22
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at least one from each competition group. Vero-furin cell–
derived WT POWV-SPO was neutralized less efficiently than a
standard preparation of WT POWV-SPO. However, standard and
Vero-furin cell–derived M-K10N POWV-SPO was neutralized
equivalently, and both M-K10N–containing viral stocks were in-
hibited more efficiently than WT POWV-SPO (Fig. 1, G and H).
Together, these data suggest that differences in virus maturation
between WT and M-K10N may contribute to differences in sen-
sitivity to antibody neutralization. However, this finding does not
explain the entire effect, as Vero-furin cell–derivedM-K10N still is
neutralized more efficiently than standard preparation of WT
POWV-SPO even though it has less uncleaved prM.
Due to the role of the N-terminal loop in regulating stability
of the mature virus particle (Füzik et al., 2018; Zhang et al.,
2013), we tested the effect of the M-K10N substitution on the
decay rate of virus infectivity. WT and K10N POWVs produced in
either Vero-furin or standard Vero cells were incubated at 37°C for
up to 48 h and then tested for infectivity using a focus-forming
assay (FFA). M-K10N POWV lost infectivity more rapidly over
time than WT POWV, and the maturation state of either virus did
not affect decay rates (Fig. 1 I). Thus, theM-K10N substitution alters
virus stability independent of virus maturation state. Loss of virus
infectivity in solution over time, or intrinsic decay, has been hy-
pothesized to be a consequence of viral “breathing” (the confor-
mational flexibility of virion surface proteins), which results in
virion structural proteins sampling ensembles of conformations, a
subset of which leads to an irreversible loss of infectivity (Carson,
2014; Goo et al., 2017; Organtini et al., 2014). Changes in viral sta-
bility resulting from the M-K10N substitution may reflect inherent
differences in viral breathing, which could in turn affect epitope
exposure, explaining the altered neutralization sensitivity patterns.
Mechanism of neutralization by anti-POWV mAbs
To probe the mechanisms of mAb neutralization, we evaluated
their capacity to inhibit POWV-MA51240 infection when added
after viral attachment to cells. A subset of mAbs was tested; for
mAbs with high sequence similarity, only one representative
mAb was selected for evaluation. POWV-70 had a fivefold re-
duction in neutralization potency when added at a postattach-
ment step, indicating it may inhibit more efficiently at a
preattachment step (Fig. 2, A and B). As all other mAbs tested
efficiently neutralized POWV after virus attachment to cells,
they likely block an entry step after cellular engagement.
ThemAbswere next evaluated for their ability to inhibit viral
fusion using a fusion-from-without (FFWO) assay (Fernandez
et al., 2018). MAbs from competition group A (POWV-4),
group D (POWV-70), group E (POWV-37, -65, -71, and -80), and
group F (POWV-60 and -61) all inhibited viral fusion (Fig. 2, C
and D). AlthoughmAbs from competition group B (POWV-5, -56,
and -63) and group C (POWV-14, -15, and -23) did not inhibit
viral fusion, this outcome might be confounded by their tem-
perature dependence of binding; these mAbs lacked the ability to
neutralize POWV in solution when they were added at 4°C but
were removed before the shift in temperature and incubation at
37°C (Fig. 2 E). Thus, these mAbs may fail to block fusion in the
FFWO assay because they do not bind efficiently to virus at 4°C.
Cross-reactivity of POWV mAbs against other flaviviruses
To assess cross-reactivity of the anti-POWV mAbs against other
TBFVs, we tested three other viruses in the TBFV clade: TBEV,
Langat virus (LGTV), and GGYV. POWV shares ∼77–78% amino
acid identity in the E protein with LGTV and TBEV and 72%
identity with GGYV. The POWVmAbs first were tested for their
ability to bind to cells transfected with the structural genes of
TBEV, LGTV, or GGYV. Several group B mAbs (POWV-54, -56,
and -63) as well as group A mAb POWV-4 cross-reacted with all
three TBFVs tested (Fig. 3 A and Table 2). Some mAbs exhibited
cross-reactivity to a subset of the TBFVs, including mAbs in
groups D and E, and the prM-E mAb POWV-16. In comparison,
mAbs in groups C and F and the remaining mAbs in group B
showed type-specific binding patterns. Thus, subsets of DIII-
and non–DIII-binding anti-POWV mAbs recognize conserved
epitopes in several TBFVs.
We next tested whether the cross-reactive mAbs could in-
hibit infection of the other TBFVs (Fig. 3 B and Table 2). POWV-
54, -56, and -63 in group B all neutralized LGTV, albeit weakly
(EC50 of 1.5, 11.5, and 2.5 µg/ml, respectively), with POWV-54
and -63 also exhibiting some cross-neutralization of GGYV RVPs
(7.8 µg/ml and 11.2 µg/ml, respectively). The cross-reactive DIII-
binding mAbs in group E also cross-neutralized other TBFVs.
POWV-33, -37, and -80 inhibited TBEV RVPs (EC50 of 1.6, 0.6,
and 8.5 µg/ml, respectively), and POWV-71 and POWV-80
neutralized LGTV infection (EC50 of 0.04 and 10.3 µg/ml,
respectively).
We evaluated whether the cross-reactivity extended to the
MBFV clade using a panel of RVPs displaying the structural
proteins of dengue virus serotype 2 (DENV-2), St. Louis en-
cephalitis virus (SLEV), Zika virus (ZIKV), yellow fever virus
(YFV), West Nile virus (WNV), and Usutu virus (USUV). We
initially assessed cross-reactivity using an antibody-dependent
experiments. (B and C) POWVmAbs were assayed for neutralization by FRNT against POWV strains SPO, MA51240, and LB. (B) Representative dose-response
curves. Error bars represent the range from two technical replicates. (C)Mean EC50 values. Error bars represent SEM from three to four experiments. (D and
E) POWVmAbs were assayed for neutralization by FRNT against POWV-SPO encodingWT sequence or an M protein K10Nmutation. (D) Representative dose-
response curves. Error bars represent the range from two technical replicates. (E) Mean EC50 values for each mAb. Error bars represent SEM from three
experiments. (F) The amount of prM on virions was measured for WT and K10N infectious clone–derived virus produced in Vero cells or Vero-furin cells (furin)
by ELISA. Error bars represent SEM from three experiments. (G and H) POWVmAbs were assayed for neutralization against standard and Vero-furin stocks of
WT and M-K10N infectious clone–derived POWV-SPO. (G) Mean EC50 values of all tested mAbs from three experiments. (H) Representative dose-response
curves. Error bars represent the range from two technical replicates. (I) The loss of virus infectivity was determined by incubation at 37°C before determination
of viral titer by FFA. Error bars represent SEM from three experiments. (C and E) Dotted lines represent the limit of detection of the assay. Statistical analysis:
ANOVA with Tukey’s post-test (C, F, and G); ANOVA with Sidak’s post-test (E); ANOVA with Dunnett’s post-test (I). *, P < 0.05; **, P < 0.01; ***, P < 0.001;
****, P < 0.0001). Ab, antibody; mat, mature; std, standard.
VanBlargan et al. Journal of Experimental Medicine 5 of 22
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Figure 2. Mechanism of neutralization by anti-POWV mAbs. (A and B) POWV mAbs were assayed for pre- or postattachment inhibition using a modified
FRNT against POWV-MA51240. (A) Representative dose-response curves. Error bars represent the range from two technical replicates. (B)Mean EC50 values
for each mAb. Error bars represent SEM from three experiments (ANOVA with Sidak’s post-test: ns, all comparisons). Dotted line represents the limit of
detection of the assay. (C and D) FFWO neutralization assays. (C) Infection levels are expressed relative to cells incubated with an isotype control mAb. Error
bars represent SEM from five independent experiments (ANOVA with Dunnett’s post-test: ***, P < 0.001; ****, P < 0.0001). Dotted line represents the isotype
control value. (D) Representative flow cytometry plots are shown. (E) Antibodies were assayed for neutralization of POWV-MA51240 by FRNT at 37°C and 4°C.
Representative dose-response curves are shown from two independent experiments. Error bars represent the range from two technical replicates. Ab, an-
tibody; SSC, side scatter.
VanBlargan et al. Journal of Experimental Medicine 6 of 22
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enhancement (ADE) assay because the required stoichiometry of
binding for ADE is less than that for neutralization (Pierson
et al., 2007). The group B cross-reactive mAbs POWV-54,
POWV-56, and POWV-63 all enhanced MBFV infection of K562
cells, whereas a type-specific antibody POWV-15 did not (Fig. 3
C). Minimal to no enhancement of the MBFVs was observed for
any of the other TBFV–cross-reactive or POWV-type–specific
mAbs. The MBFV–cross-reactive mAbs subsequently were tested
for neutralization activity against DENV-2, SLEV, and ZIKV RVPs.
POWV-54, POWV-56, and POWV-63 all cross-neutralized these
RVPs (Fig. 3 D), although the potency of inhibition was decreased
against mature particles produced in Vero-furin cells (Fig. 3 E).
Thus, these pan–flavivirus-neutralizing mAbs are maturation
state sensitive.
Epitopes recognized by anti-POWV mAbs
Because of their pan-flavivirus cross-reactivity and maturation
state dependence of neutralization, we hypothesized that
POWV-54, POWV-56, and POWV-63 might recognize an epitope
in the conserved fusion loop in DII of the E protein. To test this
idea, we performed ELISAs using recombinant WNV E protein,
with aWT protein or a variant with four mutations in the fusion
loop epitope (FLE): T76A, M77G, W101R, and L107R (Oliphant
et al., 2007; Vogt et al., 2011). Fusion loop mAb WNV-E60, DIII
mAbWNV-E24, and POWV-54 and POWV-63 all bound avidly to
WT WNV E protein (Fig. 4 A). POWV-56 displayed minimal
binding to WNV E, which is consistent with its inability to
promote ADE of WNV RVPs (Fig. 3 C). Whereas the DIII-specific
mAb WNV-E24 bound to the WNV E fusion loop mutant, WNV-
E60 and the POWVmAbs did not (Fig. 4 B). Thus, POWV-54 and
POWV-63 recognize an epitope that requires an intact DII
fusion loop.
To identify additional residues that are important for rec-
ognition by the anti-POWVmAbs, we selected for neutralization
escape mutations by serially passaging POWV-MA51240 in the
presence of antibody. The resulting viruses were sequenced, and
mutations were introduced into the POWV C-prM-E expression
plasmid. POWV RVPs bearing these mutations were produced,
and the variants were tested for neutralization by the selecting
antibody. Both type-specific mAbs in group B, POWV-5 and
POWV-18, selected for mutation at R73C in the DII b-c loop near
the fusion peptide, which conferred resistance to neutralization
by either antibody (Fig. 4, C and I). All three mAbs in group C
(POWV-14, POWV-15, and POWV-23) selected for mutation at
H62Y in DII, close to the E dimer interface, which conferred
resistance to neutralization by all three mAbs (Fig. 4, D and I).
Group DmAb POWV-70 selected for and did not neutralize virus
with mutation D231Y in DII, which is in the h-i loop on the face
opposite to the inter-dimer interface (Fig. 4, E and I). These data
indicate that epitopes recognized by mAbs in groups B, C, and D
map, at least in part, to residues in DII. POWV-80 selected a
variant S390V, which is located in the F-G loop of the lateral
ridge of DIII, and conferred resistance to neutralization of this
mAb (Fig. 4, F and I). As a control, all escape mutants also were
tested for neutralization by an antibody in a different competi-
tion group than the selecting antibody; all escape mutants were
inhibited by these other mAbs (Fig. S2, A and B)
To complement our escape mutant studies, we identified
residues important for anti-POWV mAb binding using site-
directed mutagenesis of the E protein followed by screening
for loss of mAb binding by flow cytometry. Group E mAbs
POWV-37, POWV-65, and POWV-80 showed reduced binding to
E proteins harboring mutations in the N-terminal region, B-C
loop, C-C9 loop, and F-G loop of DIII (Fig. 4, G and I; and Fig.
S2 G). Group E mAb POWV-71 exhibited reduced binding to the
Y385Amutant alone, which maps to the F-G loop in DIII (Fig. 4 G
and Fig. S2 G). Group F mAb POWV-61 lost binding only to a
mutation at K313 in the A-strand of DIII (Fig. 4, G and I; and Fig.
S2 H).
Group A mAb POWV-4 had decreased binding to residues 55,
120, and 124 in DII, although none of these were by >50% (Fig. 4,
H and I; and Fig. S2 C). Group B mAb POWV-5 exhibited di-
minished binding when mutations were introduced at residues
120, 124, and 230 of DII (Fig. 4, H and I; and Fig. S2 D). Group B
mAb POWV-56 showed reduced binding to DII mutations in the
fusion loop at residue F107 and at residue E120, establishing
fusion loop binding by this mAb. Group C mAbs POWV-14,
POWV-15, and POWV-23 all showed decreased binding to the
H62Q mutant, as well as variable reduction with mutations at
residues 55, 120, and 230 in DII (Fig. 4 H and Fig. S2 E). Group D
mAb POWV-70 did not exhibit reduced binding against any of
the domain I (DI)/DII mutants (Fig. S2 F).
Because critical residues for POWV-4 binding were not se-
lected in the site-directed mutagenesis screen, we performed
hydrogen-deuterium exchange (HDX) mass spectrometry (MS)
with recombinant POWV E protein and POWV-4, as well as with
POWV-63 to confirm DII FLE binding. MS analysis revealed that
POWV-4 binding protected peptide epitopes in DI of the E pro-
tein, specifically peptides containing residues 12–24 near the A0-
B0 loop and residues 32–43 near the C0-D0 loop (Fig. S3, A and B;
and Fig. 4 I). In contrast, POWV-63 binding protected peptides
near the DII FLE, at residues 71–91 and 109–117 as well as at
residues 243–253, which are structurally adjacent to the FLE
(Fig. S3 A and C; and Fig. 4 I).
Taken together, these data demonstrate that the non–DIII-
binding mAbs in groups B, C, and D recognize epitopes within
DII of the E protein. Group B mAbs recognize epitopes con-
taining or proximal to the DII fusion loop, whereas group C and
D mAbs bind residues in the middle section of DII. The sole
group A member, POWV-4, binds to residues in DI of the E
protein. MAbs in group E bind an epitope composed of residues
in both the C-C9 loop and the lateral ridge of DIII, whereas mAbs
in group F bind a DIII epitope that includes the A-strand.
The cross-reactive mAb POWV-80 targets the C-C9 loop of DIII
To elucidate how POWV-80 can cross-react to other TBFVs, we
solved the crystal structure of a complex of POWVDIII bound by
the antigen-binding fragment (Fab) of POWV-80 at 2.0-Å res-
olution (Fig. 5 A and Table S1 A). POWV-80 targets the con-
served, cryptic C-C9 loop epitope, which previously was
described for DENV and ZIKV mAbs (Austin et al., 2012; Zhao
et al., 2016). The majority of the contact residues in the epitope
lie in a β sheet formed by the C-C9 and F-G strands and loops,
with some involvement from N-terminal residues (Fig. 5 B). The
VanBlargan et al. Journal of Experimental Medicine 7 of 22
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Figure 3. Cross-reactivity of POWV mAbs against other flaviviruses. (A) Flow cytometric analysis of HEK-293T cells transfected with the C-prM-E
structural genes of POWV, TBEV, LGTV, or GGYV; representative histograms from one of three experiments is shown. Untransfected cells (blue); transfected
cells (red). (B) Neutralization by mAbs was assessed using an RVP-based assay (TBEV and GGYV) or FRNT (LGTV) on Vero cells. Representative dose-response
curves from two to three experiments. Error bars represent the range from two technical replicates. (C) ADE of the indicated MBFV by POWV mAbs was
VanBlargan et al. Journal of Experimental Medicine 8 of 22
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POWV-80 paratope is formed mostly by the heavy chain, with
minor light chain involvement (buried surface area of 631 Å2
versus 55 Å2, respectively; Fig. 5 C). Despite overall similarity to
other C-C9 loop mAbs, POWV-80 has more contacts in the F-G
loop than anti–DENV-2 mAb E111 and anti-ZIKV mAb ZV-64.
Furthermore, POWV-80 adopts a unique binding orientation to
DIII that aligns closely with potently neutralizing lateral ridge
antibodies (Nybakken et al., 2005; Zhao et al., 2016) rather than
other C-C9 loop mAbs (Fig. 6).
Several residues in the epitope targeted by POWV-80 are
involved in hydrogen bonding and salt-bridge formation with
the paratope (Table S1 B). Most notably, Y385 forms hydrogen
bonds with heavy chain residues H33 and Y55 on the CDR-1 and
-2 of POWV-80. Additionally, K309 and R344 form multiple salt
bridges with basic residues E102 and D114 in the POWV-80
CDR3. Whereas Y385, K309, and R344 are identical between
POWV and TBEV DIII, several other epitope residues at the
binding interface are substituted (Fig. 5 D). To understand the
impact of these substitutions on POWV-80 cross-reactivity, we
measured the binding affinity of POWV-80 to recombinant
TBEV DIII using biolayer interferometry (BLI) and compared it
to POWV E. POWV-80 binds POWV E with an affinity (KD) of
∼30 nM (Fig. 5 E and Fig. S4). POWV-80 also binds TBEV DIII
strongly, with a KD of ∼75 nM, only a small decrease relative to
POWV (Fig. 5, F and G). These results show that POWV-80 ef-
ficiently binds TBEV DIII despite multiple substitutions in its
epitope, explaining why POWV-80 neutralizes TBEV RVPs
(Fig. 3 B). Almost all of the loss in affinity is due to an increased
dissociation rate (decreased half-life) for POWV-80 binding to
TBEV DIII, as the association rates (kon) for both complexes are
nearly identical (Fig. 5, E and F).
Anti-POWV mAbs protect against POWV challenge in vivo
We tested the anti-POWV mAbs for protection against lethal
virus challenge in vivo. 7-wk-old C57BL/6J mice were adminis-
tered a 250-µg dose (12.5 mg/kg) of anti-POWV mAb as pro-
phylaxis, as well as 500 µg of an anti-Ifnar1 mAb to enhance
replication and lethality (VanBlargan et al., 2018). 1 d later, mice
were inoculated with POWV-SPO. Isotype control mAb (CHK-
263)–treated mice succumbed to infection 8–10 d after infection,
whereas mice treated with any of the DIII-binding anti-POWV
mAbs were protected (Fig. 7 A). Mice treated with non–DIII-
binding POWV mAbs showed variable outcomes (Fig. 7 B).
Treatment with group B mAbs POWV-63, -56, and -54 resulted
in 90–100% survival of infected mice, whereas other group B
mAbs (POWV-5 and -18) were not protective (0–20% survival).
Two group D mAbs, POWV-70 and -62, partially protected
against lethal POWV infection (70–80% survival), but another
group D mAb (POWV-48) did not protect (0% survival), even
though POWV-48, -62, and -70 share sequence homology and
bind a similar epitope (Table 1). Group A mAb POWV-4 and all
group C mAbs (POWV-14, -15, and -23) were partially protective
against POWV challenge (30–50% survival). Lastly, POWV-16,
the sole prM-E-binding mAb, did not confer any protection
against mortality.
To probe whether the increased neutralization by mAbs
against the M-K10N virus was associated with enhanced pro-
tection in vivo, varying doses of POWV-37 were administered to
mice 1 d before inoculation with infectious clone-derived WT or
M-K10N POWV-SPO. Following treatment with 250 µg of an
isotype control mAb, infection with either WT or M-K10N
POWV resulted in 70% lethality (Fig. 7 C). A 250-µg dose of
POWV-37 was fully protective against both WT and M-K10N
POWV challenge. However, although a 50-µg dose fully pro-
tected against POWV M-K10N challenge, this dosage conferred
less protection against WT POWV. Similarly, a 10-µg dose of
POWV-37 conferred greater protection against challenge with
POWV M-K10N than WT POWV. Thus, the increased neutrali-
zation sensitivity of POWVM-K10N translates to increased mAb
protection in vivo. Despite the differences in virus stability
in vitro noted previously, WT and M-K10N POWV infection
in vivo resulted in a similar level of lethality with equivalent
kinetics (Fig. 7 C, left panel).
We next tested the efficacy of mAbs that performed well in
the prophylaxis model in a postexposure therapeutic setting
using POWV-SPO. Mice were administered 500 µg anti-Ifnar1
mAb 1 d before virus inoculation and 250 µg anti-POWVmAb 1 d
after infection with POWV-SPO. All the mAbs tested prevented
lethal POWV infection, with POWV-37, POWV-56, and POWV-61
conferring virtually complete protection (Fig. 7, D and E).
We extended these results by assessing whether POWV-37,
-56, and -61 could protect when administered 3 d after infection.
Treatment with 250 µg of the DIII-binding mAb POWV-37 or
POWV-61 offered moderate protection against POWV challenge
(30–40% survival; Fig. 7 F). Because POWV-37 and POWV-61 are
in different competition groups, we tried combination therapy
to potentially limit the generation of escape mutants, as was
seen with monotherapy with DIII-binding mAbs against WNV
(Zhang et al., 2009). A combination of POWV-37 and POWV-61
(125 µg of each) afforded less protection against infection than
monotherapy (10% survival), possibly reflecting the lower dose
of each individual mAb. In comparison, therapeutic treatment at
day +3 with the fusion loop mAb POWV-56 substantially pro-
tected mice against POWV infection (70% survival), and a
combination therapy of POWV-56 and POWV-37 (125 µg of each)
showed a similar level of protection as monotherapy with POWV-
56. Thus, POWV-56, a fusion loop mAb, offered more protection
than DIII-binding mAbs when administered 3 d after infection.
We next evaluated whether POWV-37, -61, and -56 limit viral
burden using the prophylaxis model. Serum, spleen, brain, and
spinal cord tissues were collected 8 d after virus inoculation and
assessed by quantitative RT-PCR (qRT-PCR). Prophylaxis with
POWV-37, -56, and -61 all resulted in a ∼50-fold reduction in
viremia relative to control mAb-treated mice (Fig. 6 G).
assessed by an RVP-based assay using K562 cells. Dose-response curves from two to three experiments. (D and E) Standard (D) and mature (E) RVP
preparations were assessed for sensitivity to mAb neutralization on Raji-DCSIGNR cells. Dose-response curves are shown from three to four independent
repeats. Error bars represent the range from two technical replicates. Ab, antibody.
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Treatment with POWV-37 and -61 decreased the viral load in the
spleen by∼400–600-fold, whereas POWV-56 treatment reduced
infection ∼50-fold. Treatment with any of the POWV mAbs
greatly reduced viral RNA levels in the central nervous system
with a 6-log10 reduction in the brain and spinal cord relative to
control mAb-treated mice. Thus, POWV mAbs likely protect
against mortality because they prevent infection in the central
nervous system.
Cross-protection by POWV mAbs against TBFV challenge
in vivo
We assessed whether some of the cross-reactive mAbs could
protect against challenge with heterologous TBFVs in vivo.
POWV-54, POWV-63, and POWV-71 were administered to
C57BL/6J mice treated with anti-Ifnar1 mAb before challenge
with LGTV.Mice treated with POWV-54, POWV-63, or POWV-71
were protected from clinical disease, whereas 40% of control
mAb-treated mice developed paralysis (Fig. 8 A). Additionally,
50% of isotype control mAb-treated mice lost over 5% body
weight, with 30% of mice losing 15–30% body weight. In com-
parison, POWV-54– and POWV-63–treatedmicemaintained 95%
body weight or more, and for POWV-71–treated mice, only 20%
displayed minor (5–15%) weight loss (Fig. 8 B). POWV-54–,
POWV-63–, or POWV-71–treatedmice all had lower viremia than
isotype control mAb-treated mice with 20- to 30-fold reductions
(Fig. 8 C). Decreased viral titers also were observed in the spleen
following POWV-54 (30-fold) and POWV-63 (50-fold) treat-
ment, whereas POWV-71 was less protective (Fig. 8 D). Unex-
pectedly, viral titers in the brain were not greatly reduced
following treatment with POWV-54 (sixfold), POWV-63 (nine-
fold), or POWV-71 (fourfold; Fig. 8 E), although large reductions
in the spinal cord were observed in mice treated with POWV-54
(13,000-fold) and POWV-63 (10,000-fold; Fig. 8 F). POWV-71
treatment resulted in a smaller reduction in viral titer in the
spinal cord (500-fold). Thus, the cross-reactive mAbs POWV-54,
POWV-63, and POWV-71 protect mice against LGTV infec-
tion and disease, although POWV-71 had less activity than
POWV-54 and POWV-63 despite showing higher neutralizing
titers (Table 2).
TBEV–cross-reactive mAbs POWV-56, POWV-37, and POWV-
80were tested for their ability to protect against lethal challenge
with TBEV inWT C57BL/6J mice when administered 24 h before
infection. While only 40% of mice survived TBEV infection fol-
lowing treatment with the isotype control mAb CHK-263,
treatment with POWV-56, POWV-37, and POWV-80 resulted in
70–85% survival (Fig. 8 G).
Discussion
Neutralizing mAbs with therapeutic potential against flavivi-
ruses have been previously characterized, although no mAbs
raised specifically against POWV have been described. We de-
veloped a panel of mAbs that recognize multiple epitopes on the
POWV E glycoprotein, as well as one that engages an epitope
across prM and E. Anti-E mAbs against POWV separated into six
competition groups, with one group binding DI, three groups
recognizing epitopes on DII, and two groups binding epitopes on
DIII. Regions targeted by the DIII-binding mAbs included the
lateral ridge, C-C9 loop, and A-strand. Non–DIII-binding mAbs
principally targeted epitopes on E-DII, including the FLE, the DII
dimer interface, and the DII central interface. MAbs from all six






TBEV LGTV GGYV TBEV LGTV GGYV
None POWV-16 ++ ++






++ ++ ++ 1,480 7,818
POWV-
56
++ ++ ++ 11,477
POWV-
63




































aCross-reactivity to other TBFVs was determined by mAb binding of C-prM-
E–transfected cells by flow cytometry.
bCross-neutralization was assessed by FRNT (LGTV) or an RVP-based assay
(TBEV and GGYV) in Vero cells. Geometric mean EC50 values are from two to
three independent experiments.
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Figure 4. Mapping of anti-POWV mAb epitopes. (A and B) The indicated mAbs were tested for binding by ELISA to WT WNV E protein (A) or a WNV E
fusion loop variant (B) with T76A, M77G, W101R, and L107R mutations. Error bars represent the range from two technical replicates. Data are representative of
three experiments. (C–F) POWV RVPs encoding escape mutations were tested for neutralization by the indicated mAbs on Raji-DCSIGNR cells. WT RVPs were
compared with R73C (C), H62Y (D), D231Y (E), and S390V (F). Dose-response curves from two to four experiments. Error bars represent the range from two
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groups were neutralizing against POWV lineage I and lineage II
viruses. All DIII-binding mAbs protected against lethal POWV-
SPO challenge when administered as prophylaxis, whereas
non–DIII-binding mAbs showed a broader range of activity,
with only a subset (DII FLE mAbs) demonstrating complete
protection. DIII mAbs and DII FLE mAbs exhibited protec-
tive activity when administered as therapy after POWV-SPO
infection. MAbs from DI, DII, and DIII epitope groups cross-
reacted with other TBFVs and, in the case of the DII FLE mAbs,
against MBFV as well. Both DIII and DII FLE cross-reactive
technical replicates. (G and H) POWV mAb binding to a panel of E protein mutants. Only selected mutations in DIII (G) or DI and DII (H) of the E protein are
shown; see Fig. S2 for all tested mutations. Mean binding relative to WT is shown. Error bars represent SEM from three experiments (ANOVA with Dunnett’s
post-test: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). Dotted lines represent the isotype control value. (I) Residues determined in Fig 4, A–H and
Fig. S3 as important for binding by the indicated mAbs are highlighted on the E protein dimer of TBEV (PDB accession no. 5O6A). Residues are highlighted red,
orange, green, blue, cyan, or purple in the top E protein (in gray). The bottom E protein is colored by domain: DI is red, DII is yellow, and DIII is blue.
Figure 5. The cross-reactive mAb POWV-80 binds to the C-C9 loop of DIII. (A) 2.0-Å crystal structure of POWV DIII (SPO strain) bound by POWV-80 Fab,
depicted as a ribbon diagram. POWV-80 heavy and light chains are colored in cyan and turquoise, respectively. DIII is depicted in blue. (B) Ribbon diagram of
POWV DIII with epitope contact residue side chains shown as sticks colored cyan for heavy chain contacts, pale turquoise for light chain contacts, or blue for
dual heavy/light chain contacts. (C) Surface depiction of POWV DIII showing the buried surface area covered by POWV-80, colored as in B. (D) Sequence
alignment of POWV DIII and TBEV DIII. Contact residues in the POWV-80 epitope are colored as in B. Residues that cause loss of binding are indicated by cyan
triangles. Residues highlighted in green in the TBEV DIII sequence represent substitutions relative to POWV DIII. Numbers below contact residues indicate the
number of close contacts (<3.9-Å distance between atoms). (E) Representative BLI plot showing association-dissociation curves of POWV-80 binding to POWV
E protein. Raw traces are shown in black, with fitted curves used to generate binding constants shown as red lines. (F) Representative BLI plot showing
association-dissociation curves of POWV-80 binding to TBEV DIII. (G) Bar graph summarizing the dissociation constants calculated in E and G. Error bars
represent SD from three independent experiments.
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Figure 6. Binding orientation of POWV-80 compared with other C-C9 loop antibodies. Structures of POWV-80 (cyan and pale turquoise, C-C9 loop
antibody), ZV-67 (magenta, lateral ridge antibody), E111 (light gray, C-C9 loop antibody), and ZV-64 (dark gray, C-C9 loop antibody) docked onto the structure of
TBEV E (PDB accession no. 5O6A). The bottom set of dashed lines (smaller dashes) represents the lipid bilayer that comprises the viral envelope. The thicker
dashed line above represents the E protein shell of the virion. E(TM), E protein transmembrane domain.
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mAbs conferred protection against LGTV or TBEV infection
in vivo.
Most mAbs neutralized lineage I (LB) and lineage II (SPO)
POWV strains equivalently. However, when tested against
another lineage II strain, MA51240, a more recent isolate from
the same geographic region as POWV-SPO, the anti-E mAbs
were more inhibitory despite being raised against POWV-SPO.
Because mAbs from six unique competition groups were more
Figure 7. Anti-POWV mAbs protect against POWV challenge in vivo. (A and B) 7-wk-old C57BL/6J mice were administered 250 µg of the indicated mAb
and 500 µg of anti-Ifnar1 mAb by intraperitoneal injection 24 h before subcutaneous inoculation with 102 FFU of POWV-SPO. Survival of mice receiving DIII-
binding mAb treatment (A) and non–DIII-binding mAb treatment (B) are shown relative to mice receiving isotype control mAb (CHK-263; n = 10 per group).
(C) 4–5-week-old mice were administered indicated doses of POWV-37 (or 250 µg isotype control mAb) by intraperitoneal injection 24 h before subcutaneous
inoculation of 102 FFU of POWVWT or M K10N virus generated from the POWV-SPO infectious clone. n = 9 or 10 per group (log-rank test: *, P < 0.05). (D and
E) 7-wk-old C57BL/6J mice were administered 500 µg of anti-Ifnar1 mAb by intraperitoneal injection 24 h before subcutaneous inoculation of 102 FFU POWV-
SPO, followed by administration of 250 µg of the indicated mAb 24 h after inoculation. Mice were monitored for mortality (D) and weight loss (E) for 4 wk after
viral challenge; n = 10 per group. Mean weight change is shown; error bars represent ± SD. (F) 5-wk-old mice were inoculated with POWV-SPO and 72 h later
were administered 250 µg of each indicated mAb or 125 µg of each mAb when administered as a combination; n = 10 per group (log-rank test with Bonferroni
correction: ns when not listed; ****, P < 0.0001). (G) 5-wk-old C57BL/6J mice were administered 250 µg of the indicated mAb before subcutaneous inoculation
with POWV-SPO. At 8 d after infection, the indicated tissues were harvested, and viral load was determined by qRT-PCR. Median viral titers are shown
(Kruskal-Wallis test with Dunn’s post-test: ****, P < 0.0001). *, P < 0.05; **, P < 0.01; ***, P < 0.001. Dotted lines represent the limit of detection of the assay.
(A–G) Data are from two experiments.
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inhibitory against the POWV-MA51240 strain, we hypothesized
that a global difference in E protein epitope exposure might
broadly impact antibody neutralization, as was described for
WNV (Goo et al., 2017). Indeed, the POWV-SPO and POWV-
MA51240 strains have identical E protein sequences but vary at
M protein residue 10. Using a reverse genetics approach, we
confirmed that the K10N substitution of the M protein mediated
the difference in neutralization sensitivity between the two
lineage II strains.
Multiple factors can impact flavivirus neutralization sensi-
tivity to antibodies independent of sequence differences within
epitope–paratope interactions. The degree of virus maturation
can affect accessibility of epitopes for antibody binding, in-
cluding those targeting the highly conserved fusion loop, which
often is cryptic on fully mature virions (Nelson et al., 2008;
Stiasny et al., 2006). Although the M-K10N mutation affected
the degree of prM cleavage, this result did not explain the dis-
crepancy in neutralization sensitivity between WT and M-K10N
viruses. Changes in viral breathing, the ensemble of structural
conformations sampled by the virus particle, also can impact
epitope accessibility and neutralization sensitivity. A conse-
quence of extensive viral breathing is an enhanced decay of
virus infectivity over time (Kuhn et al., 2015). We demonstrated
that POWV-SPOM-K10N has a faster rate of intrinsic decay than
WT POWV. While most of the M protein closely associates with
the viral membrane, the M-K10 residue is located in the
N-terminal loop and is thought to stabilize the E protein dimer
by associating with DII (Füzik et al., 2018; Zhang et al., 2013). We
hypothesize that the M-K10N substitution alters the con-
formations sampled by the E protein, which increases the ex-
posure of both DII and DIII epitopes for antibody binding and
decreases the inherent stability of the virus. Remarkably, the
M-K10N variation altered neutralization sensitivity to all mAbs
tested, including DII- and DIII-specific mAbs; thus, substitutions
in the flavivirus M protein globally can affect neutralization of
anti–E protein antibodies. Although the M-K10N substitution
was detected in a virus isolated from ticks in a POWV-endemic
region (Pesko et al., 2010), its prevalence appears low; it is the
only strain of 27 available full-length POWV sequences with this
change in the Virus Pathogen Database and Analysis Resource.
The most protective anti-POWV mAbs targeted the DIII lat-
eral ridge/C-C9 loop, the DIII A-strand, and the DII FLE. Many
potently neutralizing and protective anti-flavivirus mAbs rec-
ognize DIII epitopes (Oliphant et al., 2007; VanBlargan et al.,
2016; Vratskikh et al., 2013; Wahala et al., 2009). In compari-
son, mAbs targeting the highly conserved DII FLE often are
cross-reactive yet weakly neutralize owing to the cryptic nature
of their epitope (Nelson et al., 2008; Stiasny et al., 2006).
Though DII FLE mAbs can confer protection in vivo, they often
require Fc-dependent effector functions (Vogt et al., 2011). One
exception to this is the highly protective and neutralizing
E-dimer epitope mAbs that bind a complex quaternary epitope
that includes the DII FLE (Rouvinski et al., 2015); however, an-
tibodies against this epitope have not yet been described for
Figure 8. Cross-protection by POWVmAbs against LGTV challenge in vivo. (A and B) 7-wk-old C57BL/6J mice were administered 250 µg of the indicated
mAb and 500 µg of anti-Ifnar1 mAb by intraperitoneal injection 24 h before subcutaneous inoculation with 102 FFU of LGTV. (A)Mice were scored for paralysis
following viral infection. (B)Mice were monitored for weight change for 13 d following viral infection. Mean weight change is shown. Error bars represent SEM
(ANOVA with Sidak’s post-test: **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). (C–F) At day 14 after viral challenge, serum (C), spleen (D), brain (E), and spinal
cord (F) were harvested, and viral load was determined by qRT-PCR. Median viral titers (Kruskal-Wallis ANOVA with Dunn’s post-test: *, P < 0.05; ***, P <
0.001; ****, P < 0.0001). Data are from two experiments. Dotted lines represent the limit of detection of the assay. (G) C57BL/6J mice were administered 250
µg of the indicated mAb by intraperitoneal injection 24 h before subcutaneous inoculation with 104 FFU of TBEV; n = 25 per group (log-rank test with
Bonferroni correction: ns, P > 0.0167; *, P < 0.0167; **, P < 0.01). Data are from three experiments.
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TBFVs. Notably, in our study, the DII FLE mAb POWV-56 was
more protective than DIII-specific mAbs POWV-37 and POWV-
61 when administered after infection. The cross-reactive DII FLE
mAbs POWV-54, POWV-56, and POWV-63 also protected against
heterologous viral challenge with either LGTV or TBEV, despite
lower neutralization potency against those viruses. Whether the
effector functions of DII FLE mAbs are required for their ther-
apeutic efficacy requires further study.
In addition to the DII FLE mAbs, several of the DIII-specific
mAbs that recognize a lateral ridge/C-C9 loop epitope were
cross-reactive, cross-neutralizing, and protective against LGTV
and TBEV. Protective anti-ZIKV mAbs similarly were identified
that bind epitopes on the DIII-LR and C-C9 loop on ZIKV and
cross-react with DENV1 (Robbiani et al., 2017; Sapparapu et al.,
2016; Zhao et al., 2020). Thus, the DIII–LR/C-C9 loop epitope
represents an antigenic site that can be targeted by multiple
MBFV and TBFV members.
In our panel of anti-POWV mAbs, DI-, DII-, and DIII-specific
mAbs neutralized POWV infection at a postattachment step,
likely through inhibition of fusion to the host cell membrane.
Many anti-flavivirus antibodies, including both DIII and DII-FLE
mAbs, previously were shown to block infection at postattach-
ment steps (Füzik et al., 2018; Gollins and Porterfield, 1986; Lai
et al., 2007; Nybakken et al., 2005; Thompson et al., 2009). Thus,
this common mechanism of inhibition for highly neutralizing
anti-flavivirus antibodies also extends to anti-POWV mAbs.
Structural analysis of POWV-80, an antibody that neutralizes
in vitro and protects in vivo, revealed that it targets the C-C9 loop
epitope on DIII, with some engagement of the F-G loop. Align-
ment of the structure of POWV-80 bound to POWV DIII with
those of several other antibodies to heterologous flaviviruses
showed that POWV-80 adopts a binding orientationmore similar
to the potently neutralizing lateral ridge antibodies than other
C-C9 loop mAbs. This orientation may be sterically more favor-
able for binding of POWV-80 than other C-C9 loop antibodies, as
the bulk of the constant region is oriented perpendicular to the
surface of the virus, whereas other C-C9 loop mAbs bind in the
plane of the viral envelope. This may explain why POWV-80 is
more potently neutralizing than other C-C9 loop antibodies
against DENV and ZIKV (Shrestha et al., 2010; Zhao et al., 2016).
Despite several substitutions in the epitope footprint of
POWV-80 between POWV and TBEV, POWV-80 still binds with
relatively high affinity to TBEV DIII and can neutralize TBEV
in vitro and protect from TBEV infection in vivo. Although 4 of
the 18 residues in the epitope are substituted, only one of these is
conservatively changed (D388E). This shows that POWV-80
maintains high-affinity binding due to the conserved nature of
the major contact residues. LGTV contains only one substitution
in these residues (S390N), and POWV-80 displays a similar
neutralization potency against LGTV as TBEV, suggesting that
multiple substitutions may be necessary to abrogate the cross-
reactivity of POWV-80 binding.
In summary, we have described a unique panel of neutral-
izing mAbs with therapeutic potential against an emerging tick-
borne viral infection. Antibodies against both the DII FLE and
the DIII lateral ridge/C-C9 loop are cross-reactive and broadly
neutralizing and confer protection in vivo against multiple
TBFVs. These results provide insight into the protective com-
ponents of the humoral immune response to POWV, which may
inform the design of vaccines and antibody therapeutics against
POWV and other clinically relevant TBFVs.
Materials and methods
Viruses
POWV lineage I strain LB (Mandl et al., 1993) was isolated from a
human brain sample. POWV lineage II (DTV) strain SPO was
isolated from an adult deer tick (Ebel et al., 1999). LGTV strain E5
was derived from strain TP21 (Campbell and Pletnev, 2000).
POWV-LB, POWV-SPO, and LGTV were obtained from World
Reference Center for Emerging Viruses and Arboviruses (K.
Plante and S. Weaver, University of Texas Medical Branch,
Galveston, TX). POWV strain MA51240 was isolated from ticks
collected inWisconsin (Brackney et al., 2008). Virus stocks were
propagated on Vero cells and used at passages 3 and 4. Infectious
clone–derived viruses for WT and M-K10N POWV-SPO were
produced in BHK21 cells as previously described (Kenney et al.,
2018), followed by propagation for one passage on Vero cells.
Mature virus stocks were propagated in Vero-furin cells
(Mukherjee et al., 2016). Viral titer was determined by FFA on
Vero cells as described (VanBlargan et al., 2018). TBEV strain
Sofjin was provided by Dr. Michael Holbrook (National Institute
of Allergy and Infectious Disease/National Institutes of Health
[NIH], Bethesda, MD) and propagated in Vero cells. Viral titer
was determined by limiting dilution plaque assay. All work with
infectious TBEV was performed in the BSL4 facility at NIH
Rocky Mountain Laboratories in accordance with approved bi-
osafety protocols.
Cells
Cell lines were maintained at 37°C in the presence of 5% CO2.
HEK-293T and BHK-21 cells were passaged in DMEM (In-
vitrogen) supplemented with 10% FBS (Omega Scientific) and
100 U/ml penicillin-streptomycin (P/S; Invitrogen). Vero cells
were passaged in DMEM supplemented with 5% FBS and 100
U/ml P/S. Vero cells that overexpress furin (Vero-furin;
Mukherjee et al., 2016) were maintained as WT Vero cells with
the addition of 5 µg/ml blasticidin. Raji B lymphoblast cells
stably expressing the C-type lectin DC-SIGNR (Raji-DCSIGNR;
Davis et al., 2006) were cultured in RPMI 1640 medium (In-
vitrogen) supplemented with 7% FBS and 100 U/ml P/S.
Mice
Animal studies were performed in accordance with the recom-
mendations in the Guide for the Care and Use of Laboratory
Animals of the NIH. The protocols were approved by the Insti-
tutional Animal Care and Use Committee at the Washington
University School of Medicine (Assurance number A3381-01).
Protocols with TBEV in mice were approved by the NIH Rocky
Mountain Laboratory Institutional Animal Care and Use Com-
mittee. Virus inoculations were performed under anesthesia
that was induced and maintained with ketamine hydrochloride
and xylazine, and all efforts were made to minimize animal
suffering.
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C57BL/6J mice were purchased from The Jackson Laboratory
and housed in a pathogen-free animal facility at Washington
University in St. Louis or in the ABSL4 facility for TBEV studies.
For passive transfer studies, mAbs were diluted in PBS and ad-
ministered to mice via intraperitoneal injection in a 100-µl total
volume. Viral infections with POWV-SPO or LGTV were per-
formed via subcutaneous inoculation in the footpad with 102
focus-forming units (FFU) of virus. For LGTV and POWV-SPO
(where indicated) infection, 0.5 mg anti-Ifnar1–blocking mAb
MAR1-5A3 (Sheehan et al., 2006) was administered 1 d before
inoculation via intraperitoneal injection. Animals were moni-
tored for mortality (POWV) or weight loss and clinical score
(LGTV). To evaluate clinical disease following LGTV challenge, cages
were blinded, and mice were scored each day as having (a) no dis-
ease, (b) hind limb weakness or disrupted righting reflex, (c) partial
hind limb paralysis, (d) complete paralysis of one hind limb, or (e)
complete paralysis of both hind limbs. For TBEV, 104 PFUs of virus
was inoculated into the ear pinnae in 20 µl. Animals were weighed
daily and euthanized when an animal showed signs of limb paresis
or lost 20% or more of its starting weight.
Plasmids
Plasmids DTVp1 and DTVp2 for the construction of the POWV-
SPO infectious clone were described previously (Kenney et al.,
2018). For the production of RVPs, the plasmid encoding a
subgenomic replicon of the WNV lineage II strain 956 that
expresses GFP (WNVrepG/Z) and plasmids expressing the
C-prM-E structural genes of POWV strain P0375 (GenBank ac-
cession no. KU886216), TBEV strain Neudoerfl (GenBank ac-
cession no. U27495), LGTV strain TP21 (GenBank accession no.
NC_003690), GGYV strain Macquarie Island (GenBank acces-
sion no. DQ235145), DENV-2 strain 16681 (GenBank accession
no. U87411), ZIKV strain H/PF/2013 (GenBank accession no.
KJ776791), and WNV strain NY99 (GenBank accession no.
KC407666) have been reported (Ansarah-Sobrinho et al., 2008;
Dowd et al., 2016b; Pierson et al., 2006; VanBlargan et al., 2018).
Plasmids that express the C-prM-E structural genes of SLEV
strain Kern 217 (GenBank accession no. DQ525916), YFV strain
17D-204 (GenBank accession no. KF769015), and USUV strain
Vienna 2001 (GenBank accession no. AY453411) were cloned into
the expression vector pcDNA3.1 (Invitrogen). All plasmid prop-
agation and cloning procedures were performed using Stbl2
bacteria grown at 30°C (Invitrogen).
mAb generation
One group of C57BL/6J mice was inoculated with 102 FFU of
POWV-SPO, boosted 6 wk later with 2 × 102 FFU POWV-SPO,
and given a final intravenous boost with 5 × 106 FFU of POWV-
SPO 3 d before splenocyte collection. A second group of C57BL/
6J mice was immunized twice (4 wk apart) with a lipid
nanoparticle–encapsulated modified mRNA vaccine encoding
the POWV prM and E genes (VanBlargan et al., 2018) and given
a final intravenous boost of recombinant E (ectodomain) or DIII
proteins 3 d before splenocyte collection. Subsequently, sple-
nocytes were fused with P3X63.Ag.6.5.3 myeloma cells.
Hybridomas producing antibodies that were bound to POWV-
infected Raji-DCSIGNR cells by flow cytometry and/or POWV
E by direct ELISA were cloned by limiting dilution. All hy-
bridomas were screened initially with a single-endpoint RVP-
based neutralization assay using neat hybridoma supernatant
incubated with POWV RVPs for 1 h at 37°C. Raji-DCSIGNR cells
were added to mAb-virus, incubated for 2 d, and assayed for
GFP expression by flow cytometry. Hybridoma supernatants
with >60% neutralization were purified commercially (Bio-X
Cell) after adaptation for growth under serum-free conditions.
POWV E protein preparation
POWV-SPO soluble E ectodomain (E residues 1–397) and DIII
(E residues 297–397 of E) were cloned into pET21a (Invitrogen)
by Gibson assembly. Plasmids were transformed into BL21(DE3)
cells (Invitrogen), and protein expressionwas induced by adding
a 1:5 mixture of glucose and lactose to the culture and growing
on a shaker overnight at 37°C. Proteins were expressed as in-
clusion bodies, which were purified, denatured, and refolded by
slow dilution into a large volume of oxidative refolding buffer
(400 mM arginine, 100 mM Tris-HCl, 1 mm EDTA, pH 8.3, 2.5%
wt/vol glycerol, 10 mM reduced glutathione, 1 mM oxidized
glutathione, and 2.5 mM phenylmethylsulfonyl fluoride). The
refolded E protein was concentrated and dialyzed against 10 mM
Tris, pH 8.0, overnight before being purified across a HiTrap Q
HP column (GE Life Sciences) followed by size-exclusion chro-
matography on an S75 increase column (GE Life Sciences). DIII
was purified by affinity capture using Ni-NTA resin (GoldBio)
followed by size exclusion chromatography on an S75 column
(GE Life Sciences).
Competition ELISA
Nunc MaxiSorp plates (Thermo Fisher Scientific) were coated
with 4 µg/ml POWV-SPO E protein in 100 µl sodium bicarbonate
coating buffer (0.1 M Na2CO3, 0.1 M NaHCO3, and 0.02% NaN3,
pH 9.6) and incubated overnight at 4°C. Plates were washed
three times with ELISA wash buffer (PBS containing 0.05%
Tween-20) and then incubated with 200 µl blocking buffer
(PBS, 2% BSA, 0.05% Tween-20, and 0.025% NaN3) for 2 h at
room temperature. Blocking buffer was removed, and plates
were incubated with 25 µl of each anti-POWV mAb (20 µg/ml)
diluted in blocking buffer. After an incubation for 1 h at room
temperature, 25 µl of a biotinylated version of each anti-POWV
mAb (2 µg/ml) was added directly to the plates and incubated for
1 h at room temperature. Biotinylation was performed using an
EZ-Link NHS-PEG4-Biotin kit (Thermo Fisher Scientific) ac-
cording to manufacturer instructions. Plates were washed three
times with ELISA wash buffer and incubated with 50 µl
streptavidin-HRP (Invitrogen; diluted 1:40,000 in ELISA wash
buffer) for 1 h at room temperature. Plates were washed three
times and then incubated with 100 µl of 3,39,5,59-tetrame-
thylbenzidine (TMB) substrate (Thermo Fisher Scientific) for
3 min at room temperature before quenching by addition of
50 µl of 2 N H2SO4 and measuring with a microplate reader at
OD 450 nm.
Virion prM content
Nunc MaxiSorp plates (Thermo Fisher Scientific) were coated
with 5 µg/ml POWV-55 in 100 µl NaHCO3 (pH 9.6) coating
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buffer and incubated overnight at 4°C. Plates were washed three
times with ELISAwash buffer (PBS containing 0.05% Tween-20)
and then incubated with 200 µl blocking buffer (PBS, 2% BSA,
and 0.05% Tween-20) for 2 h at room temperature. Plates were
incubated with 3 × 105 FFU of virus diluted in DMEM sup-
plemented with 2% FBS for 1 h at 37°C. Plates were fixed with 1%
paraformaldehyde (PFA) for 10 min at room temperature,
followed by extensive washing with PBS. Plates then were incu-
bated with 100 µl biotinylated POWV-16 (anti-prM) or POWV-56
(anti-E) mAbs diluted in blocking buffer for 1 h at 37°C. Plates were
washed three times with ELISA wash buffer and incubated with
50 µl streptavidin-HRP diluted (1:625) in PBS for 20 min at room
temperature. Plates were washed again and then incubated with
100 µl TMB substrate (Thermo Fisher Scientific) for 3 min at room
temperature before quenching with the addition of 50 µl of 2 N
H2SO4 and measuring at OD 450 nm. The relative prM signal was
calculated by dividing the OD450measurement of POWV-16 signal
by the OD450 measurement for POWV-56, multiplied by 100.
RVPs
RVPs were produced by the genetic complementation of a DNA-
launched, WNV subgenomic replicon with a C-prM-E expres-
sion plasmid, as described previously (Ansarah-Sobrinho et al.,
2008). Briefly, preplated HEK-293T cells were cotransfected
with WNVrepG/Z, a WNV replicon expressing GFP, and the
C-prM-E expression plasmids described above using FugeneHD
(Promega) in accordance with the manufacturer’s instructions.
Transfected cells were incubated at 37°C, and supernatant was
harvested at 48 h after transfection, filtered using a 0.22-µm
syringe filter, and stored at −80°C. RVPs were produced using
the genetic complementation of plasmids as described above;
however, HEK-293T cells were transfected using Lipofectamine
3000 transfection reagent (Invitrogen). These transfected cells
were incubated at 30°C, and RVP-containing supernatants were
harvested daily, pooled, and then filtered through a 0.22-mm
filter (Millipore) and stored at −80°C. The infectious titer of
RVPs was assayed using Raji-DCSIGNR cells or Vero cells, as
described previously (Mukherjee et al., 2014).
Neutralization assays
(a) RVP neutralization assays were performed as described
(Mukherjee et al., 2014). Briefly, RVP stocks were diluted so that
∼3–5% of cells become infected and incubated with serial dilu-
tions of serum for 1 h at 37°C before the addition of Raji-
DCSIGNR cells or Vero cells. Infections were performed at
37°C for 48 h, and infectivity was scored as the percentage of
GFP-expressing cells determined by flow cytometry. (b) FRNTs
were performed as described for other flaviviruses (Brien et al.,
2013). Briefly, serial dilutions of serum were incubated with 2 ×
102 FFU of POWV for 1 h at 37°C. Immune complexes were added
to Vero cell monolayers and incubated for 1 h at 37°C before the
addition of 1% (wt/vol) methylcellulose in MEM. Following in-
cubation for 3 d at 37°C, cells were fixed with 1% PFA, per-
meabilized with 0.1% saponin, and stained for infection foci with
POWV-16 (1 µg/ml). For both RVP neutralization assays and FRNT,
antibody-dose response curves were analyzed using nonlinear
regression analysis (with a variable slope and the top of the curve
constrained to 100; GraphPad Software). Data are expressed as the
serum dilution required to reduce infection by half (EC50).
Intrinsic virus decay
Loss of viral infectivity was measured by incubating 105 FFU of
virus (diluted in DMEM supplemented with 2% FBS) at 37°C for
various lengths of time before collection of media and storage at
−80°C. Viral titer was determined by FFA.
Pre- and postattachment neutralization assays
For preattachment assays, serial dilutions of mAbs were prepared at
4°C in DMEM with 2% FBS and preincubated with 102 FFU of
POWV-MA51240 for 1 h at 4°C.mAb–virus complexeswere added to
a monolayer of Vero cells for 1 h at 4°C. Virus was allowed to in-
ternalize during a 37°C incubation for 1 h. Cells were overlaid with
1% (wt/vol)methylcellulose inMEMsupplementedwith 4% FBS. For
postattachment assays, 5 × 102 FFU of POWV-MA51240 was ad-
sorbed onto amonolayer of Vero cells for 1 h at 4°C. After removal of
unbound virus, serial dilutions of mAbs were added to virus-
adsorbed cells for 1 h at 4°C. Virus then was allowed to internalize
for 1 h at 37°C, and subsequently cells were overlaid with methyl-
cellulose as described above. 3 d later, the plates were fixed with 1%
PFA and analyzed for antigen-specific foci as described above.
FFWO neutralization assay
FFWO neutralization assays were performed by incubating
prechilled Vero cells with POWV MA51240 (multiplicity of in-
fection of 200) for 2 h at 4°C. Unbound virus was removed, and
50 µg of the indicated anti-POWVmAbs was incubated with the
cells for 1 h at 4°C. Cells were washed and incubated with RPMI
supplemented with 0.2% BSA, 10 mM Hepes, and 30 mM suc-
cinic acid and adjusted to pH 5.5. RPMI without succinic acid at
pH 7.4 was used as a control to determine the background level
of infection. Cells were incubated with the acidic media for 7min
at 37°C. After the cells were rinsed with DMEM supplemented
with 2% FBS and 10 mM Hepes, cells were incubated with
DMEM supplemented with NH4Cl for 24 h at 37°C. Cells were
then trypsinized, fixed with 1% PFA, permeabilized with HBSS
with 5% FBS and 1% (wt/vol) saponin, stained with POWV-16
followed by Alexa Fluor 647–conjugated secondary antibody
(Invitrogen), and analyzed for infection by flow cytometry.
Generation of escape mutants
Escape mutants were generated by blind passaging of POWV-
MA51240 in the presence of increasing concentrations of mAb
for five passages on Vero cells. Virus from passage 5 was tested
for neutralization sensitivity by FRNT, and subsequently viral
RNAwas isolated and used tomake cDNA, which was sequenced.
Amino acid mutations detected in the sequencing reactions were
introduced in the POWV C-prM-E plasmid and used to produce
RVPs, which were tested for neutralization as described above.
Site-directed mutagenesis epitope mapping
To identify amino acids on the E protein important for mAb
binding, we narrowed down target residues for mutagenesis by
selecting residues that differed between POWV and LGTV or
GGYV, as many of the antibodies we mapped did not cross-react
VanBlargan et al. Journal of Experimental Medicine 18 of 22








niversity In St. Louis Libraries user on 29 April 2021
against subsets of these viruses. In the case of mAbs that did
cross-react against both (POWV-56 and -63), mAb binding was
decreased against GGYV. We focused on residues predicted to be
exposed on the surface of the virion. Surface accessibility was
estimated using solvent-accessible surface areas of the residues
determined from the structure of the TBEV E protein dimer
(Protein Data Bank [PDB] accession no. 5O6A), with a cutoff
value of 30 Å2 (University of California, San Francisco Chimera
package). We expanded our mutagenesis of DIII to include ad-
ditional residues on the lateral ridge. Residues were mutated to
the corresponding residue in GGYV or LGTV or, in the case of the
additional DIII residues, to alanine or lysine (when the residue
was a glycine). Mutations were introduced into the POWV
C-prM-E plasmid described above. In total, 98 mutants were
generated, although somewere excluded due to low transfection
efficiency. Each mutant was transfected into HEK-293T cells; 48 h
later, cellswere fixedwith 1%PFA, permeabilizedwithHBSSwith 5%
FBS and 1% (wt/vol) saponin (referred to as permeabilization buffer),
and incubated with mAbs at concentrations optimized for staining
(range, 14–4,000 ng/ml) and Alexa Fluor 647–conjugated secondary
antibody (Invitrogen) in permeabilization buffer. Fluorescence signal
was detected by flow cytometry (MacsQuant) and analyzed using
FlowJo software. The percentage of positively stained cells was cal-
culated relative to mock-transfected cells. Transfection efficiency for
each mutant was normalized using the percentage of cells stained
with anti-POWV polyclonal mouse serum. Antibody reactivity
against each mutant was compared with that of the WT C-prM-E
after subtracting the signal from mock-transfected controls.
Cross-reactivity of mAbs
Cross-reactivity against other TBFVs was assessed by transfecting
HEK-293T cells with the POWV, TBEV, LGTV, or GGYV C-prM-E
plasmids described above. 48 h later, cells were fixed and per-
meabilized as described above and then incubated with mAbs at
10 µg/ml and Alexa Fluor 647–conjugated secondary antibody (In-
vitrogen) in permeabilization buffer. Fluorescence signal was de-
tected by flow cytometry. Cross-reactivity against MBFVs was
assessed by ADE assays as described previously (Mukherjee
et al., 2014). Briefly, serial dilutions of Mab were incubated
with RVPs of the indicated MBFVs for 1 h at 37°C and subse-
quently added to K562 cell monolayers. Cells were incubated
at 37°C for 2 d, and infectivity was scored as the percentage of
GFP-expressing cells determined by flow cytometry.
BLI
Biotinylated POWV mAbs were diluted to 5 µg/ml in BLI buffer
(HBS-EP+, 3% wt/vol BSA) and loaded onto streptavidin pins in an
Octet Red 96 system (ForteBio). Subsequently, the pins were
dipped into various dilutions of recombinant POWV E protein or
TBEV DIII in BLI buffer to measure association kinetics followed
by blank BLI buffer to measure dissociation kinetics. Binding af-
finities were calculated as the ratio of the off-rate to the on-rate
determined from curves fitted to the association-dissociation data.
Crystallization of POWV-80 with DIII
Concentrated POWV Fab fragments were mixed with a stoichio-
metric excess of recombinant untagged POWVDIII at 4°C for >2 h.
The mixture was then purified over an S75 size-exclusion column
to isolate Fab:DIII complexes in 20mMHepes, pH 7.4, and 150mM
NaCl. The complex was concentrated to 13.5 mg/ml. POWV-80–
DIII complexes were crystallized by hanging drop vapor diffusion
by adding 0.5 µl of the complex to 0.5 µl of 0.16 M NH4SO4,
0.08 M NaCH3COOH, 20% wt/vol glycerol, and 16% wt/vol poly-
ethylene glycol 4000, pH 4.6.
Structure determination and refinement
Diffraction data were collected at Advanced Light Source beamline
4.2.2 (Molecular Biology Consortium) at 100K using awavelength of
1.0 Å, with a CMOS detector in shutter-less mode. The diffraction
data were processed with XDS, then scaled and merged with Aim-
less.Molecular replacementwas done in PHENIX using the PHASER
GUI (Adams et al., 2010; Evans andMurshudov, 2013; Kabsch, 2010;
McCoy et al., 2007). Molecular replacement of POWV-80 and DIII
was accomplished by truncating the structure of the TBEV envelope
(PDB accession no. 1SVB) to DIII and mutating residues to match the
sequence of POWV. For the Fab, the sequence of POWV-80 heavy
chain was used as a search term for BLAST to find a structure of a
sequentially homologous Fab (PDB accession no. 3UO1), which was
subsequently split into N-terminal and C-terminal variable and
constant-domain searchmodels. Amodel fitting the electron density
map was built manually using Coot (Emsley et al., 2010) and refined
with PHENIX. A summary of data collection and refinement statis-
tics is provided in Table S1. Structures were visualized using Uni-
versity of California, San Francisco ChimeraX (Goddard et al., 2018).
Buried surface area was calculated using ChimeraX. Interfacial res-
idues were identified using QtPISA. Structural data have been de-
posited in the PDB under accession no. 7KYL.
HDX-MS
Peptide mapping
To prepare for acquisition and analysis of HDX data, a peptide map
(in triplicate) of POWV E protein was generated by liquid chroma-
tography/MS/MS using a Thermo LTQ Orbitrap XL mass spec-
trometer. POWV E (100 pmol) was admitted to the mass
spectrometer operating in a data-dependent fragmentation mode
andmonitoring the six most abundant peptides. Data were analyzed
by Byonic (Protein Metrics) for sequencing and accurate precursor
mass (±5 ppm), and the peptides were manually curated.
Given three disulfide bonds of POWV E, digestion had to be
optimized for sequence coverage by adjusting the reducing agent
concentration (Tris (2-carboxyethyl) phosphine hydrochloride
[TCEP]), denaturant (guanidine hydrochloride [GdnHCl]), and
incubation time. The final optimized conditions were 1:1 dilution
of HDX reaction volume (100 µl) with quench buffer containing
500 mM TCEP and 4 M GdnHCl, pH 2.4 (250 mM TCEP, 2 M
GdnHCl and pH 2.6 final), 3-min incubation, 25°C.
HDX
POWV E was equilibrated with or without antibody in PBS (pH
7.0) at 10°C for 30 min and then exchanged in with D2O in the
presence and absence of antibody by diluting the protein (100
pmol, 10 µl) by 10-fold with PBS in D2O at 10°C (90 µl, pH 7.0).
HDX was measured at 0 (undeuterated control), 10, 60, 300, and
4,100 s at 10°C. For the undeuterated control, the conditions were
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the same except the added buffer solution was H2O instead of D2O.
TheHDXwas quenched by adding an equal volume of quench buffer
equilibrated at 45°C followed by mixing and incubation at room
temperature to give a final temperature after mixing of ∼25°C.
The quenched sample was digested by passing through a
custom-packed column (2 mm × 20 mm) of immobilized pepsin
beads followed by a column of immobilized Fungal XIII beads at
200 µl/min flow rate. The resulting peptides were captured and
desalted on a Zorbax Eclipse XDB-C8 trap (Agilent) column by
using 0.1% formic acid in water for 4.7 min. Desalted peptides
were loaded on a C18 analytical column (2.1 × 50 mm in size, 2.5
µm Xselect-CSH from Waters) where peptides were separated
using a gradient of acetonitrile (ACN) in 0.1% formic acid (most
peptides eluted during the linear part of gradient from 5min [4%
ACN] to 15 min [40% ACN]). To minimize back exchange, the
trap and analytical columns were kept in an ice slush. The iso-
tope distributions of the exchanged peptides were measured
with a Thermo Fisher Scientific LTQ Orbitrap XL MS (MS only
mode) for duplicate samples.
HDX data analysis
Liquid chromatography–MS HDX data acquisition (retention time,
isotopic distribution, and observedm/z) was directed by the peptide
map, and data were analyzed by HDExaminer (Sierra Analytics).
The maximum deuterium level was normalized to 90%, and the
data were displayed as kinetic plots for each peptide for HDX. To
elucidate those regionswhereHDX changed upon antibody binding,
the mean cumulative differences (bound–unbound) across all the
time points for each peptide were calculated and plotted as aWoods
plot. To identify significant difference upon binding, global SEM
was calculated according to published methods (Hageman and
Weis, 2019). Protected regions upon binding showed negative cu-
mulative percent deuteration (%D), whereas regions exposed upon
binding gave positive cumulative %D.
Measurement of viral burden
Mice were sacrificed on the indicated days after infection and
perfused extensively with PBS, and the indicated organs were
collected. Organs were weighed and homogenized using a
MagNA Lyser (Roche). Viral RNA from homogenized organs or
serum was isolated using the MagMAX Viral RNA Isolation Kit
(Thermo Fisher Scientific) and measured by TaqMan one-step
qRT-PCR on an ABI 7500 Fast Instrument. Viral burden is ex-
pressed on a log10 scale as viral RNA equivalents per gram or
milliliters after comparison with a standard curve produced
using serial 10-fold dilutions of viral RNA from known quanti-
ties of infectious virus. POWV-SPO primers (Platt et al., 2018)
were 59-GCAGCACCATAGGTAGAATGT-39, 59-CCACCCACTGAA
CCAAAGT-39, and probe 59-/56-FAM/TCTCAGTGG/Zen/TTG
GAGAACACGCAT/3IABkFQ-39. LGTV primers (VanBlargan et al.,
2018) were 59-GGAACTAGGCCTTGCAGAAT-39, 59-TGTTCTCCA
TTGTCGGGTTAG-39, and probe 59-/56-FAM/TGAGGTTAA/Zen/
CGTGGCCATGCTCAT/3IABkF-39.
Statistical analysis
Data analyses were performed using Prism software Version 7.0
(GraphPad Software). Log EC50 values were compared by one-
way ANOVA followed by Sidak’s multiple comparisons test
(when comparing a subset of values) or Tukey’s multiple com-
parisons test (when comparing all values). For survival analysis,
Kaplan-Meier curves were plotted and analyzed by the log-rank
test with a Bonferroni correction for multiple comparisons.
Weight loss experiments were compared by an ANOVA with
Sidak’s multiple comparisons test. Viremia and viral burden in
tissues were compared by Kruskal-Wallis test followed by
Dunn’s post-test.
Online supplemental material
Fig. S1 shows Western blotting of POWV-infected cell lysates
with POWV-16, mAb variable region sequence homology, and the
location of residue M-K10N within (pr)M. Fig. S2 shows com-
plete site-directed mutagenesis mapping results and neutrali-
zation of escape mutants with a control antibody. Fig. S3 shows
HDX-MS results. Fig. S4 shows kinetic binding curves of mAbs to
POWV E protein. Table S1 shows x-ray crystallography data and
contact residues between POWV-80 and POWV DIII.
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Figure S1. Characteristics of POWV mAbs and POWV E-M heterodimer. (A) POWV-infected cell lysates were tested for reactivity with POWV-4 and
POWV-16 by Western blotting. The E protein is ∼50 kD and prM is ∼18 kD. Blots shown are representative data from three experiments. (B) Alignment of
CDR3 sequences of related mAbs; differences are highlighted in red. (C) Sequence conservation and phylogram of antibody VH sequences. Numbers indicate
the percent amino acid identity shared between VH sequences of respective mAbs. (D) Schematic of pr(M), showing the furin cleavage site and the relative
position of the M-K10 residue. (E) The residue corresponding to POWV M residue K10 is highlighted on mature structure of the TBEV E-M heterodimer (PDB
accession no. 5O6A).
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Figure S2. Epitopes recognized by anti-POWV antibodies. (A and B) Escape mutants from Fig 4, C–F were tested for neutralization by mAbs that bind an
epitope distinct from the antibody that selected for their growth. (A) Mutations in DII were tested for their effect on POWV RVP neutralization by DIII mAb
POWV-60. (B) DIII mutant S390V was tested for neutralization by non-DIII mAb POWV-70. (C–H) Anti-POWV mAbs were tested for binding to the indicated E
protein mutants encoding single amino acid changes in DI and DII (C–F) or DIII (G and H); binding relative to WT is shown. Error bars represent SEM from three
experiments (ANOVA with Dunnett’s post-test: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). Colored bars represent statistically significant
decreases in binding, P < 0.05. Dotted lines represent the isotype control value.
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Figure S3. HDX of E protein bound to POWV-4 and POWV-63. (A) Representative kinetic plots for 12 different peptides showing effects of antibody binding
on HDX. Black, blue, and red lines are for POWV E in the absence of antibody, in the presence of POWV-4 mAb, and in the presence of POWV-63 mAb,
respectively. At the top of each panel are the residue numbers and charge states of the peptide, and sequences of each peptide are given as a table. Error bars
represent SEM from duplicate measurements. (B and C) Woods plots showing accumulated difference in %D (bound state–unbound state) across all time
points for each analyzed peptide for POWV-4 (B) and POWV-63 (C). Central and outer gray shaded areas indicate 95% and 99% confidence intervals, re-
spectively, for the global SEM calculated for each differential HDX experiment.
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Figure S4. Association-dissociation curves for POWVmAbs binding to POWV E protein. (A) Representative association-dissociation curves for all POWV
mAbs that bound to recombinant E protein. Black lines indicate raw data; red lines show fits used to derive binding affinity constants. Each plot represents one
of at least three independent experiments used to generate summary dissociation constants and binding half-lives in Table 1.
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Provided online is Table S1, which shows x-ray crystallography dataset processing, model refinement, and validation statistics, and
summarizes interfacial contacts between POWV-80 and POWV DIII.
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